REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$16.06 USD
+0.02 (0.12%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $16.09 +0.03 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RGNX 16.06 +0.02(0.12%)
Will RGNX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RGNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGNX
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
RGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
Other News for RGNX
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Edgewise gets EU orphan drug status for muscular dystrophy drug
Where Regenxbio Stands With Analysts
Commit To Purchase REGENXBIO At $7.50, Earn 10.1% Annualized Using Options
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD